Publication Date: 09 Apr 2013
Citation: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7 7-15
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
PDF (538.25 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
This is the first time I have published published an article in Clinical Medicine Insights Case Report. I was pleased to find that the publishing staff were helpful in guiding my submission and I was impressed by the prompt processing and speed of publication.